Literature DB >> 30276121

Limb-Threatening Arterial Thrombosis in a Patient with Eosinophilic Granulomatosis with Polyangiitis.

Taylor Braunberger1, Jessica S Mounessa2, Ryan O'Leary2, Ekama Carlson2, Sabrina Newman2.   

Abstract

Eosinophilic granulomatosis (EGPA), or Churg-Strauss syndrome, is a rare and necrotizing systemic vasculitis, which affects small-to-medium-sized vessels and often manifests with severe asthma and eosinophilia. We report a case of a 72 year-old male with a two-year lung-biopsy proven history of EGPA who presented with retiform purpura and patchy necrosis on his bilateral shins, which progressed to sharply demarcated, stellate ulcerations with surrounding erythema within two weeks. Laboratory work up revealed elevated anti-Cardiolipin IgM, rheumatoid factor, erythrocyte sedimentation rate, and C-reactive protein, although P-neutrophil cytoplasmic antibody (P-ANCA) and C-neutrophil cytoplasmic antibody (C-ANCA) were negative. Vascular studies revealed long anterior tibial and dorsalis pedis artery occlusion and severe small vessel disease in plantar digital arteries. Despite treatment with intravenous cyclophosphamide, pulse-dose methylprednisolone, and pentoxifylline, the patient experienced disease progression and limb threatening arterial thrombosis. This case highlights the importance of vascular and neuropathic sequelae that may result from untreated or undertreated EGPA in P-ANCA-negative patients without active pulmonary symptoms.

Entities:  

Keywords:  Churg-Strauss syndrome; Eosinophilic granulomatosis with polyangiitis; Gangrene; P-ANCA; Thrombosis

Year:  2017        PMID: 30276121      PMCID: PMC6161628          DOI: 10.1016/j.jccw.2017.03.001

Source DB:  PubMed          Journal:  J Am Coll Clin Wound Spec        ISSN: 2213-5103


  9 in total

1.  Histopathological features predictive of a clinical diagnosis of ophthalmic granulomatosis with polyangiitis (GPA).

Authors:  Hazlita Isa; Sue Lightman; Philip J Luthert; Geoffrey E Rose; David H Verity; Simon R J Taylor
Journal:  Int J Clin Exp Pathol       Date:  2012-09-05

Review 2.  Churg-Strauss syndrome.

Authors:  Christian Pagnoux; Philippe Guilpain; Loïc Guillevin
Journal:  Curr Opin Rheumatol       Date:  2007-01       Impact factor: 5.006

3.  Prothrombotic state in Churg-Strauss syndrome: a case report.

Authors:  A V Marzano; A Tedeschi; R Rossio; D Fanoni; M Cugno
Journal:  J Investig Allergol Clin Immunol       Date:  2010       Impact factor: 4.333

4.  The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis).

Authors:  A T Masi; G G Hunder; J T Lie; B A Michel; D A Bloch; W P Arend; L H Calabrese; S M Edworthy; A S Fauci; R Y Leavitt
Journal:  Arthritis Rheum       Date:  1990-08

5.  Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) presenting with polyneuropathy--a case series.

Authors:  Fernando Santos-Pinheiro; Yuebing Li
Journal:  J Clin Neuromuscul Dis       Date:  2015-03

6.  A nationwide survey on the epidemiology and clinical features of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) in Japan.

Authors:  Ken-Ei Sada; Koichi Amano; Ritei Uehara; Masahiro Yamamura; Yoshihiro Arimura; Yoshikazu Nakamura; Hirofumi Makino
Journal:  Mod Rheumatol       Date:  2013-12-02       Impact factor: 3.023

Review 7.  Optimal therapy and prospects for new medicines in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).

Authors:  Christian Pagnoux; Matthieu Groh
Journal:  Expert Rev Clin Immunol       Date:  2016-06-06       Impact factor: 4.473

Review 8.  Eosinophilia and thrombophilia in churg strauss syndrome: a clinical and pathogenetic overview.

Authors:  Paul R J Ames; Maurizio Margaglione; Sara Mackie; José Delgado Alves
Journal:  Clin Appl Thromb Hemost       Date:  2009-10-14       Impact factor: 2.389

Review 9.  Eosinophils in vasculitis: characteristics and roles in pathogenesis.

Authors:  Paneez Khoury; Peter C Grayson; Amy D Klion
Journal:  Nat Rev Rheumatol       Date:  2014-07-08       Impact factor: 20.543

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.